Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

Core Insights - Lifecore Biomedical has been selected by Nirsum Laboratories to provide contract development and manufacturing organization (CDMO) services for the clinical development of NRS-033, a treatment for opioid use disorder (OUD) and alcohol use disorder (AUD) [1][2][5] - The agreement includes technology transfer and assessment of the fill and finish process for NRS-033, leveraging Lifecore's expertise in sterile injectable pharmaceutical products [1][3] - NRS-033 aims to address the high relapse rates associated with current therapies for OUD and AUD, with the potential to improve therapeutic retention for patients [3][5] Company Overview - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of experience and serves global and emerging biopharmaceutical and biotechnology companies [4] - Nirsum Laboratories is a development-stage biotechnology company focused on creating curable treatments for addiction, with NRS-033 being funded in part by the NIH [5]